Connect with us

Hi, what are you looking for?

Bnreport Business News Report


EU agency backs first COVID-19 treatment

The European Medicines Agency (EMA) Thursda..

The European Medicines Agency (EMA) Thursday recommended a conditional marketing authorization for remdesivir as a COVID-19 treatment.

The EMA said remdesivir, produced by Gilead, can be used to treat patients over the age of 12 whose COVID-19 symptoms include pneumonia and who need oxygen therapy.

Conditional marketing authorization allows the EMA to recommend a medicine for early access in an emergency.

This means the medicine might be recommended with less data than a typical marketing authorization, provided that the agency determines that “the benefit of a medicines immediate availability to patients outweighs the risk,” the agency explained.

The Commissions decision, which is being fast-tracked, should follow “in the coming week,” according to a press release.

The EMA began a rolling review of remdesivir at the end of April, and it recommended expanding the compassionate use of the medicine on May 11.

The EMA based Thursdays recommendation on a study by the U.S. National Institute of Allergy and Infectious Diseases (NIAID). It showed that patients with severe COVID-19 symptoms recovered more quickly than those who received a placeboRead More – Source



You May Also Like


Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae.


Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.


Enlarge/ You wouldn't really want to use Nvidia's ..


Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora.

%d bloggers like this: